or liver biopsy. Negative results do not exclude the possibility of cancer and further follow-up is necessary. Although hepatocellular carcinoma (HCC) has always been recognized as a complication ...

EvoLiver, a blood test that detects early-stage liver cancer with high accuracy, has gained breakthrough device designation ...

Helio Genomics ("Helio" or "the Company"), an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, today showcased results from three cancer ...

Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to significantly improve cancer outcomes for at-risk ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Pierre Arsène, founder and CEO of Mursla Bio, said: “This designation is a powerful validation of both our scientific vision ...

Mursla Bio, a Cambridge UK and Boston US leader in Extracellular Vesicle (EV) science, has received FDA approval for its lead ...

Prevalence and risk factors Hepatocellular carcinoma (HCC), the most common type of primary liver cancer ... “And when that doesn’t suffice, a biopsy will be carried out,” he explained.

The company said that its test could overcome sensitivity issues with ultrasound and serum alpha-fetoprotein assays that are used to monitor at-risk patients.

The fig summarizes the main treatment strategies for HCC. Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, accounting for the majority of primary liver cancer cases.

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...